Category Archives: Global News Feed

TORONTO, March 24, 2022 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX - XLY) (OTCQX: CBWTF) ("Auxly" or the "Company"), a leading consumer packaged goods company in the cannabis products market, announced today that it will report earnings results for its fourth quarter and full year ended December 31, 2021, on Thursday March 31, 2022, before the financial markets open.

See the rest here:
Auxly to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022

-- Proposal of one-tier board structure & appointment of three new directors --Mechelen, Belgium; 24 March 2022, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 2021 and announces extraordinary and annual shareholders’ meetings to be held sequentially on Tuesday 26 April 2022 at 1:00 p.m. (CET) and 2:00 p.m. (CET), respectively, at the registered office of the Company.

Original post:
Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings

Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs

Follow this link:
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Continued Progress Towards Optimizing Clinical Development Plans

Go here to see the original:
Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update

Basel, 25 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data for its approved and investigational medicines across neurological disorders will be presented at the 74th American Academy of Neurology (AAN) Annual Meeting being held 02-07 April in Seattle and virtually 24-26 April 2022. These data include twenty-four abstracts highlighting Roche’s expansive neuroscience portfolio across five therapeutic areas, including OCREVUS® (ocrelizumab) in relapsing, secondary and primary progressive multiple sclerosis (RMS, SPMS and PPMS), EVRYDSI™ (risdiplam) in spinal muscular atrophy (SMA), ENSPRYNG™ (satralizumab) in neuromyelitis optica spectrum disorder (NMOSD), along with data from investigational programs in Alzheimer’s disease (AD) and Duchenne muscular dystrophy (DMD).

See the rest here:
Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting

Live video webcast presentation on Wednesday, January 26th at 10:00 AM ET Live video webcast presentation on Wednesday, January 26th at 10:00 AM ET

View post:
AIM ImmunoTech to Present at the Virtual Investor 2022 Top Picks Conference

Company honored for commitment to improve gender representation across ranks and promote women to leadership roles Company honored for commitment to improve gender representation across ranks and promote women to leadership roles

Continue reading here:
Parexel Named 2022 Catalyst Award Winner

New manufacturing process increases the final yield of nomacopan by at least 5-fold thereby significantly lowering the cost of goods for clinical studies and commercialization New manufacturing process increases the final yield of nomacopan by at least 5-fold thereby significantly lowering the cost of goods for clinical studies and commercialization

Originally posted here:
FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies

Accomplished academic and industry veteran with a successful record developing treatments for B cell lymphoma Accomplished academic and industry veteran with a successful record developing treatments for B cell lymphoma

Read the original post:
Foresight Diagnostics Establishes Scientific Advisory Board with Appointment of Sandra Horning, M.D.

Clearmind’s Management Team Will Explain the Regulatory Process Required for Clearmind’s Patented MEAI Molecule to Become an FDA Approved Medicine for Treating Alcohol Use Disorder and Binge Drinking

Read this article:
Clearmind Medicine to Host “Psychedelic for Alcoholism: From Molecule to Medicine” Virtual Event on January 26